by Peter Ciszewski | Oct 1, 2021
Rare diseases and orphan drugs are at the forefront of novel development and groundbreaking research. Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs. Below is the list of important regulatory dates for all...
by Peter Ciszewski | Sep 30, 2021
Julie Dohm, Of Counsel at Covington & Burling based in Silver Spring, Maryland, discusses some of the important issues that physicians and patients should understand regarding drug compounding. Between 2016 and 2019, Julie served as the lead on compounding...
by Peter Ciszewski | Sep 30, 2021
Avanish Vellanki, Cofounder and CEO at Rain Therapeutics, discusses the role of p53 and MDM2 in cancers like liposarcoma, the mechanism of action of milademetan, and the positive pre-clinical data presented at the 2021 World Conference of Lung Cancer. As Mr....
by Peter Ciszewski | Sep 29, 2021
Jonathan Rigby, MD, President, Group CEO, and Board Member at Revolo Biotherapeutics, discusses the approval of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA) to evaluate the drug, ‘1104, in a phase 2 trial for...
by Peter Ciszewski | Sep 29, 2021
James Cassidy, MD, PhD, Chief Medical Officer at SpringWorks Therapeutics, gives an overview of Desmoid tumors. As Dr. Cassidy explains, Desmoid tumors are tumors that can grow anywhere on the body into surrounding healthy tissues, including joints, muscle, and...
